TAP completes Phase II studies of ilaprazole

Published: 2007-08-24 06:59:00

Updated: 2007-08-24 06:59:00

The U.S.-based TAP Pharmaceutical Products Inc. has completed a Phase II test for ilaprazole, a new investigational proton pump inhibitor (PPI) in the United States, said an official at Ilyang Pharm on August 22.

TAP signed Ilyang for the development and distribution of ilaprazol in 2005 and h...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK